Optimal therapy for Helicobacter pylori infections

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 2, 2011, Pages 79-88

  Rimbara, Emiko ^a   Fischbach, Lori A ^b   Graham, David Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BACTERIAL PROTEIN; BISMUTH CITRATE; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; FLAVINE MONONUCLEOTIDE REDUCTASE; HELIDAC; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; OMEPRAZOLE; OXYGEN INSENSITIVE NITROREDUCTASE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RNA 23S; TETRACYCLINE; TINIDAZOLE; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME IMMUNOASSAY; ERADICATION THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; TREATMENT DURATION;

AMOXICILLIN; ANTI-INFECTIVE AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 79751495793     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.210     Document Type: Review

References (123)

1. Kandulski, A. et al. Helicobacter pylori infection: a clinical overview. Dig. Liver Dis. 40, 619-626 (2008).
2. Sarai, A. S. et al. Helicobacter pylori, a causative agent of vitamin B12 deficiency. J. Infect Dev. Ctries 2, 346-349 (2008).
3. Shiotani, A. & Graham, D. Y. Pathogenesis and therapy of gastric and duo (Pubitemid 36008457)
4. Graham, D. Y. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115, 1272-1277 (1998). (Pubitemid 28485620)
5. Graham, D. Y. & Shiotani, A. New concepts of resistance in the treatment of Helicobacter pylori nfections. Nat Clin. Pract Gastroenterol. Hepatol. 5, 331 (2008).
6. Megraud, F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53, 1374-1384 (2004). (Pubitemid 39120130)
7. Megraud, F. Helicobacter pylori and antibiotic resistance. Gut 56, 1502 (2007). (Pubitemid 350033185)
8. Gisbert, J. P The recurrence of Helicobacter pylori nfection: incidence and variables influencing it. A critical review. Am. J. Gastroenterol. 100, 2083-2099 (2005).
9. Graham, D. Y. Helicobacter pylori eradication therapy research: ethical issues and description of results. Clin. Gastroenterol. Hepatol. (in press).
10. Fischbach, L. A., Goodman, K. J., Feldman, M. & Aragaki, C Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int. J. Epidemiol. 31, 128-139 (2002). (Pubitemid 34284915)
11. Borody, T. J. et al. Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 37, 477-481 (1995).
12. Borody, T. J. et al. Optimal H. pylori (HP) therapy\a combination of omeprazole and triple therapy (TT). Gastroenterology 106, A55 (1994).
13. De Boer, W. A. How to achieve a near 100% cure rate for H. pylori infection in peptic ulcer patients. A personal viewpoint. J. Clin. Gastroenterol. 22, 313-316 (1996). (Pubitemid 26001162)
14. Graham, D. Y & Fischbach, L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 59, 1143-1153 (2010).
15. Graham, D. Y et al. Practical rapid, minimally nvasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter 10, 1-3 (2005). (Pubitemid 40269367)
16. Osato, M. S. et al. Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J. Antimicrob. Agents 17, 39-44 (2001). (Pubitemid 32008658)
17. Osato, M. S. et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch. Intern. Med. 161, 1217-1220 (2001). (Pubitemid 32691518)
18. Van der Wouden, E. J. et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am. J. Gastroenterol. 94, 1751-1759 (1999). (Pubitemid 29315882)
19. Graham, D. Y et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol. Ther. 24, 845-850 (2006).
20. Dore, M. P et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig. Dis. Sci. 45, 68-76 (2000). (Pubitemid 30111690)
21. Bardhan, K. et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 5, 196-201 (2000). (Pubitemid 34948000)
22. Versalovic, J. et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 40, 477-480 (1996). (Pubitemid 26049364)
23. Taylor, D. E. et al. Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob. Agents Chemother. 41, 2621-2628 (1997). (Pubitemid 27524731)
24. Versalovic, J. et al. Point mutations in the 23S rRNA gene of Helicobacter pylori associated with different levels of clarithromycin resistance. J. Antimicrob. Chemother. 40, 283-286 (1997). (Pubitemid 27394025)
25. Toracchio, S. et al. Identification of a novel mutation affecting domain V of the 23S rRNA gene in Helicobacter pylori. Helicobacter 9, 396-399 (2004). (Pubitemid 39273942)
26. Fontana C, et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob. Agents Chemother. 46, 3765-3769 (2002). (Pubitemid 35403249)
27. Rimbara, E. et al. Novel mutation in 23S rRNA that confers low-level resistance to clarithromycin in Helicobacter pylori. Antimicrob. Agents Chemother. 52, 3465-3466 (2008).
28. Moore, R. A. et al. Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob. Agents Chemother. 39, 107-111 (1995).
29. Wang, G. et al. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob. Agents Chemother. 45, 727-733 (2001). (Pubitemid 32182016)
30. Nishizawa, T. et al. Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan. Antimicrob. Agents Chemother. 50, 1538-1540 (2006).
31. Miyachi, H. et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 11, 243-249 (2006). (Pubitemid 44051350)
32. Wang, L. H. et al. Distribution of gyrA mutations in fluoroquinolone- resistant Helicobacter pylori strains. World J. Gastroenterol. 16, 2272-2277 (2010).
33. Hoffman, P S. et al. Metabolic activities of metronidazole-sensitive and-resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance. J. Bacteriol. 178, 4822-4829 (1996). (Pubitemid 26321281)
34. Kwon, D. H. et al. Analysis of rdxA and nvolvement of additional genes encoding NAD(P) H flavin oxidoreductase (FrxA) and ferredoxin-like protein (FdxB) in metronidazole resistance of Helicobacter pylori. Antimicrob. Agents Chemother. 44, 2133-2142 (2000).
35. Chisholm, S. A. & Owen, R. J. Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J. Antimicrob. Chemother. 51, 995-999 (2003). (Pubitemid 36503434)
36. Marais, A. et al. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res. Microbiol. 154, 137-144 (2003). (Pubitemid 36324505)
37. Rimbara, E. et al. Mutations in penicillin-binding proteins 1, 2 and 3 are responsible for amoxicillin resistance in Helicobacter pylori. J. Antimicrob. Chemother. 61, 995-998 (2008). (Pubitemid 351524437)
38. Okamoto, T. et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. J. Antimicrob. Chemother. 50, 849-856 (2002). (Pubitemid 36040323)
39. Gerrits, M. M. et al. Multiple mutations in or adjacent to the conserved penicillin-binding protein motifs of the penicillin-binding protein 1A confer amoxicillin resistance to Helicobacter pylori. Helicobacter 11, 181-187 (2006). (Pubitemid 43736553)
40. Furuta, T. et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection. Clin. Gastroenterol. Hepatol. 3, 564-573 (2005). (Pubitemid 40824749)
41. Vecsei, A. et al. Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children. Clin. Gastroenterol. Hepatol. 8, 309-312 (2010).
42. Lottspeich, C et al. Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J. Clin. Microbiol. 45, 1718-1722 (2007). (Pubitemid 46933897)
43. Noguchi, N. et al. Detection of mixed clarithromycin-resistant and-susceptible Helicobacter pylori using nested PCR and direct sequencing of DNA extracted from faeces. J. Med. Microbiol. 56, 1174-1180 (2007). (Pubitemid 47477188)
44. Schabereiter-Gurtner, C et al. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J. Clin. Microbiol. 42, 4512-4518 (2004). (Pubitemid 39362364)
45. Menard, A. et al. PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with Helicobacter pylori resistance to clarithromycin. Antimicrob. Agents Chemother. 46, 1156-1157 (2002). (Pubitemid 34260374)
46. Stone, G. G. et al. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Helicobacter pylori. Antimicrob. Agents Chemother. 41, 712-714 (1997). (Pubitemid 27098432)
47. Marais, A. et al. Direct detection of Helicobacter pylori resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. Gut 44, 463-467 (1999). (Pubitemid 29169944)
48. Pina, M. et al. Detection of point mutations associated with resistance of Helicobacter pylori to clarithromycin by hybridization in liquid phase. J. Clin. Microbiol. 36, 3285-3290 (1998). (Pubitemid 28476180)
49. Maeda, S. et al. Detection of clarithromycin-resistant Helicobacter pylori strains by a preferential homoduplex formation assay J. Clin. Microbiol. 38, 210-214 (2000). (Pubitemid 30043290)
50. Van Doorn, L. J. et al. Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob. Agents Chemother. 43, 1779-1782 (1999).
51. Gibson, J. R. et al. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J. Clin. Microbiol. 37, 3746-3748 (1999). (Pubitemid 29491131)
52. Oleastro, M. et al. Real-Time PCR Assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J. Clin. Microbiol. 41, 397-402 (2003). (Pubitemid 36098606)
53. Lascols, C et al. Fast and accurate quantitative detection of Helicobacter pylori and identification of clarithromycin resistance mutations in H. pylori isolates from gastric biopsy specimens by real-time PCR. J. Clin. Microbiol. 41, 4573-4577 (2003). (Pubitemid 37259759)
54. Burucoa, C et al. Quadruplex real-time PCR assay using allele-specific scorpion primers for detection of mutations conferring clarithromycin resistance to Helicobacter pylori. J. Clin. Microbiol. 46, 2320-2326 (2008).
55. Matsumura, M. et al. Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. J. Clin. Microbiol. 39, 691-695 (2001). (Pubitemid 32150840)
56. Alarcon, T. et al. PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in Helicobacter pylori clinical isolates. J. Clin. Microbiol. 38, 923-925 (2000). (Pubitemid 30082714)
57. Furuta, T. et al. Modified allele-specific primer-polymerase chain reaction method for analysis of susceptibility of Helicobacter pylori strains to clarithromycin. J. Gastroenterol. Hepatol. 22, 1810-1815 (2007). (Pubitemid 47525091)
58. Nakamura, A. et al. Determination of mutations of the 23S rRNA gene of Helicobacter pylori by allele specific primer-polymerase chain reaction method. J. Gastroenterol. Hepatol. 22, 1057-1063 (2007). (Pubitemid 47019849)
59. Nishizawa, T. et al. Rapid detection of point mutations conferring resistance to fluoroquinolone in gyrA of Helicobacter pylori by allele-specific PCR. J. Clin. Microbiol. 45, 303-305 (2007).
60. Cambau, E. et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori J. Clin. Microbiol. 47, 3600-3607 (2009).
61. Yilmaz, O. et al. Detection of Helicobacter pylori and determination of clarithromycin susceptibility using formalin-fixed, paraffin-embedded gastric biopsy specimens by fluorescence in situ hybridization. Helicobacter 12, 136-141 (2007).
62. Vega, A. E. et al. Detection of clarithromycin-resistant Helicobacter pylori in frozen gastric biopsies from pediatric patients by a commercially available fluorescent in situ hybridization. Diagn. Microbiol. Infect. Dis. 59, 421-423 (2007). (Pubitemid 350184231)
63. Morris, J. M. et al. Evaluation of seaFAST, a rapid fluorescent in situ hybridization test, for detection of Helicobacter pylori and resistance to clarithromycin in paraffin-embedded biopsy sections. J. Clin. Microbiol. 43, 3494-3496 (2005). (Pubitemid 40981376)
64. Russmann, H. et al. Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization. J. Clin. Microbiol. 41, 813-815 (2003). (Pubitemid 36184203)
65. Cellini, L. et al. Analysis of genetic variability antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand. J. Gastroenterol. 41, 280-287 (2006).
66. Hung, K. H. et al. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter 14, 61-65 (2009).
67. Essa, A. S. et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 14, 109-118 (2009).
68. Gisbert, J. P et al. Sequential therapy for Helicobacter pylori eradication: a critical review. J. Clin. Gastroenterol. (in press).
69. Gatta, L. et al. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am. J. Gastroenterol. 104, 3069-3079 (2009).
70. Graham, D. Y. et al. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs 68, 725-736 (2008). (Pubitemid 351550527)
71. Hsu, P I. et al. Search for a grade A therapy for Helicobacter pylori infection: 14-day sequential or sequential-concomitant hybrid therapy Gastroenterology 138 (Suppl. 1), S111 (2010).
72. Fischbach, L. A. et al. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol. Ther. 20, 1071-1082 (2004). (Pubitemid 39657940)
73. Luther, J. et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am. J. Gastroenterol. 105, 65-73 (2010).
74. O'Morain, C et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol. Ther. 17, 415-420 (2003). (Pubitemid 36259404)
75. Laine, L. et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 98, 562-567 (2003). (Pubitemid 36348526)
76. Malfertheiner, P. et al. Quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline, and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori. Gastroenterology 138 (Suppl. 1), S33 (2010).
77. Graham, D. Y. et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol. Ther. 14, 745-750 (2000). (Pubitemid 30352741)
78. Frenck, R. W. et al. Helicobacter in the developing world. Microbes Infect 5, 705-713 (2003).
79. WHO. The global burden of disease: 2004 update [online] http://www.who.int/healthinfo/global burden disease/2004 report update/en/index.html (2008).
80. Mathers, C D. & Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3, e442 (2006).
81. National Cancer Institute. A snapshot of stomach (gastric) cancer [online], http://www.cancer.gov/aboutnci/servingpeople/cancer-snapshots (2009).
82. Fischbach, L. & Evans, E. L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol. Ther. 26, 343-357 (2007). (Pubitemid 47063149)
83. Ramirez-Ramos, A. et al. Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. Clin. Infect Dis. 25, 1027-1031 (1997).
84. Ahuja, V. & Sharma, M. P High recurrence rate of Helicobacter pylori infection in developing countries. Gastroenterology 123, 653-654 (2002). (Pubitemid 34827211)
85. Bell, G. D. & Powell, K. U. Helicobacter pylori reinfection after apparent eradication\the pswich experience. Scand. J. Gastroenterol. Suppl. 215, 96-104 (1996).
86. Parsonnet, J. What is the Helicobacter pylori global reinfection rate? Can. J. Gastroenterol. 17 (Suppl.), 46B-48B (2003).
87. Graham, D. Y. et al. A report card to grade Helicobacter pylori therapy. Helicobacter 12, 275-278 (2007). (Pubitemid 47196342)
88. Kepekci, Y. & Kadayifci, A. Does the eradication of Helicobacter pylori cure duodenal ulcer disease in communities with a high prevalence rate? Comparison with long-term acid suppression. Int. J. Clin. Pract 53, 505-508 (1999).
89. Figueroa, G. et al. Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients. Am. J. Gastroenterol. 91, 1395-1399 (1996). (Pubitemid 26236377)
90. Ciok, J., Dzieniszewski, J. & Lucer, C Helicobacter pylori eradication and antral ntestinal metaplasia\two years follow-up study. J. Physiol. Pharmacol. 48 (Suppl. 4), 115-122 (1997). (Pubitemid 127699216)
91. Goh, K. L. et al. Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. Eur. J. Gastroenterol. Hepatol. 8, 1157-1160 (1996).
92. Kumar, D. et al. Randomized trial of a quadruple-drug regimen and a triple-drug regimen for eradication of Helicobacter pylori: long-term follow-up study Indian J. Gastroenterol. 20, 191-194 (2001). (Pubitemid 32937658)
93. Mitchell, H. M. et al. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). Gastroenterology 114, 256-261 (1998). (Pubitemid 28093531)
94. Silva, F M. et al. Helicobacter pylori reinfection in Brazilian patients with peptic ulcer disease: a 5-year follow-up. Helicobacter 15, 46-52 (2010).
95. Bapat, M. R. et al. Acquisition of Helicobacter pylori infection and reinfection after its eradication are uncommon in Indian adults. Indian J. Gastroenterol. 19, 172-174 (2000).
96. Aydin, A. et al. Low reinfection rate of Helicobacter pylori infection in Turkey. J. Clin. Gastroenterol. 30, 337 (2000). (Pubitemid 30194653)
97. Louw, J. A. et al. Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence. Gut 36, 544-547 (1995).
98. Ashour, A. A. et al. Distribution of vacA genotypes in Helicobacter pylori strains isolated from Brazilian adult patients with gastritis, duodenal ulcer or gastric carcinoma. FEMS Immunol. Med. Microbiol. 33, 173-178 (2002). (Pubitemid 34756563)
99. Zhou, L. et al. A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin. Med. J. (Engl.) 116, 11-14 (2003). (Pubitemid 36432713)
100. Ahmad, M. M. et al. Long-term re-infection rate after Helicobacter pylori eradication in Bangladeshi adults. Digestion 75, 173-176 (2007). (Pubitemid 350202459)
101. Mera, R. et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 54, 1536-1540 (2005). (Pubitemid 41531767)
102. Oona, M. et al. Long-term recurrence rate after treatment of Helicobacter pylori infection in children and adolescents in Estonia. Scand. J. Gastroenterol. 39, 1186-1191 (2004). (Pubitemid 39656832)
103. Zendehdel, N. et al. Helicobacter pylori reinfection rate 3 years after successful eradication. J. Gastroenterol. Hepatol. 20, 401-404 (2005). (Pubitemid 40469340)
104. Mach, T. & Zahradnik-Bilska, J. Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication. Przegl. Lek. 56, 477-482 (1999).
105. Della Libera, E. et al. Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates. Braz. J. Med. Biol. Res. 34, 753-757 (2001). (Pubitemid 32613087)
106. Hildebrand, P et al. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology 121, 792-798 (2001). (Pubitemid 32959389)
107. Kyzekove, J. et al. Is there any relationship between functional dyspepsia and chronic gastritis associated with Helicobacter pylori nfection? Hepatogastroenterology 48, 594-602 (2001). (Pubitemid 32391620)
108. Leal-Herrera, Y et al. High rates of recurrence and of transient reinfections of Helicobacter pylori in a population with high prevalence of nfection. Am. J. Gastroenterol. 98, 2395-2402 (2003). (Pubitemid 37448747)
109. Konar, A. et al. Natural history of severe duodenal ulcer disease. Indian J. Gastroenterol. 17, 48-50 (1998). (Pubitemid 28180289)
110. Karczewska, E. et al. Oral cavity as a potential source of gastric reinfection by Helicobacter pylori. Dig. Dis. Sci. 47, 978-986 (2002). (Pubitemid 34439172)
111. Soto, G. et al. Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J. Infect Dis. 188, 1263-1275 (2003). (Pubitemid 37433696)
112. Wheeldon, T. U. et al. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol. Ther. 21, 1047-1053 (2005).
113. Andreson, H. et al. Persistence of Helicobacter pylori infection in patients with peptic ulcer perforation. Scand. J. Gastroenterol. 42, 324-329 (2007).
114. Gunaid, A. A. et al. Recurrence of Helicobacter pylori infection 1 year after successful treatment: prospective cohort study in the Republic of Yemen. Eur. J. Gastroenterol. Hepatol. 16, 1309-1314 (2004). (Pubitemid 39627530)
115. Gurel, S. et al. After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. J. Clin. Gastroenterol. 28, 241-244 (1999). (Pubitemid 29141105)
116. Mansour-Ghanaei, F et al. Recurrence of Helicobacter pylori infection 1 year after successful eradication: a prospective study in Northern Iran. Med. Sci. Monit 16, CR144-CR148 (2010).
117. Gabryelewicz, A. et al. Multicenter evaluation of dual-therapy (omeprazol and amoxycillin) for Helicobacter pylori-associated duodenal and gastric ulcer (two years of the observation). J. Physiol. Pharmacol. 48 (Suppl. 4), 93-105 (1997). (Pubitemid 127699214)
118. Coelho, L. G. et al. Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. Scand. J. Gastroenterol. 27, 362-366 (1992).
119. Najafi, M. S. et al. Reinfection rate after successful Helicobacter pylori eradication in children. Iran. J. Ped. 20, 58-62 (2010).
120. Hoffenberg, P et al. Comparison of 2 treatment schemes to eradicate Helicobacter pylori. Rev. Med. Chil. 123, 185-191 (1995).
121. Konturek, P C et al. Epidermal growth factor and transforming growth factor alpha in duodenal ulcer and non-ulcer dyspepsia patients before and after Helicobacter pylori eradication. Scand. J. Gastroenterol. 33, 143-151 (1998). (Pubitemid 28098228)
122. Eisig, J. N. et al. Helicobacter pylori recurrence in patients with duodenal ulcer: clinical, endoscopic, histologic, and genotypic aspects. A 10-year Brazilian series. Helicobacter 11, 431-435 (2006). (Pubitemid 44352613)
123. Jarosz, M. et al. Dietary and socio-economic factors in relation to Helicobacter pylori re-infection. World J. Gastroenterol. 15, 1119-1125 (2009).